THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 93, No. 10, 1998 Copyright 1998 by Am. Coll. of Gastroenterology ISSN /98/$19.
|
|
- Stuart Ray
- 6 years ago
- Views:
Transcription
1 THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 93, No. 10, 1998 Copyright 1998 by Am. Coll. of Gastroenterology ISSN /98/$19.00 Published by Elsevier Science Inc. PII S (98) Cure of Helicobacter pylori Infection and Healing of Duodenal Ulcer: Comparison of Pantoprazole-Based One-Week Modified Triple Therapy Versus Two-Week Dual Therapy Romuald J. Adamek, M.D., Thomas D. Bethke, M.D., and The International Pantoprazole HP Study Group Department of Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany; Department of International Clinical Research, Byk Gulden, Konstanz, Germany; and The International Pantoprazole HP Study Group: in Austria, B. Brandstätter, L. Kasses, P. Kratochvil, W. Weiss, H. Wurzer; in Germany, G. Beetz, H. Bock, G. Bretzke, G. Büttner, K. Eichhorn, H. Hebbeln, E. Hommel, D. Hüppe, W. Hüttemann, M. Kirchhof, H. Klann, J. Labenz, W. Martens, C. Naumann, B. Pfaffenbach, I. Rehmann, H. G. Rohner, U. Schink, W. Schmeisser, E. Schütz, G. Tangerding, H. Wübbolding; in Switzerland, C. Beglinger, R. Meier Objective: Eradication of Helicobacter pylori (H. pylori) is recommended as the first-line therapeutic concept for reliable long-term prevention of duodenal ulcer (DU) relapse. Current treatment regimens vary in efficacy, complexity, and compliance. To assess the efficacy of pantoprazole in in parallel groups of patients using two eradication regimens. Methods: Patients, (18 85 yr old; intention-to-treat, n 286) with proven DU, positive rapid urease test (biopsy), and 13 C-urea breath test (UBT) were included in a prospective, randomized, multicenter study. Modified triple therapy consisted of 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days (PCM therapy); dual therapy consisted of 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days (PC therapy). In both groups 40 mg pantoprazole o.d. was given until day 28 when healing of DU was evaluated endoscopically; H. pylori status was assessed by UBT on day 56. Results: rate was 95% in PCM versus 60% in PC therapy groups (perprotocol population, p < 0.001), and 82% in PCM versus 50% in PC therapy in the intention-to-treat patient population (p < 0.001). The DU healing rate was 98% in the PCM and 95% in the PC therapy groups (per-protocol population). Both regimens were similarly well tolerated. Adverse events in both regimens included taste disturbance, diarrhea, and increased serum concentration of liver enzymes, at an incidence of < 10%. Conclusions: Compared to 2-wk PC therapy (pantoprazole and clarithromycin), the 1-wk PCM therapy (pantoprazole, clarithromycin, and metronidazole) is a significantly superior and highly promising strategy for eradication of H. pylori. (Am J Gastroenterol 1998;93: by Am. Coll. of Gastroenterology) Received Dec. 29, 1997; accepted June 1, INTRODUCTION Based on evidence from interventional trials it is now well accepted that the spiral Gram-negative bacterium Helicobacter pylori (H. pylori), which colonizes gastric mucosa in humans, is not only a causative agent in chronic active gastric diseases but also contributes to the pathogenesis of chronic relapsing duodenal ulcer disease (for review, see Reference (1). Eradication of H. pylori by medications administered for a limited period is recommended as the first-line therapeutic approach, leading to reliable long-term prophylaxis of duodenal ulcer relapse (2 5). Indeed, the eradication of this microorganism has accelerated healing of duodenal ulcers even in patients refractory to some of the antisecretory drugs (6, 7), prevented ulcer complications, and significantly improved the quality of life of those affected (8 10). In addition, cure of H. pylori represents the most economic approach in the long-term management of duodenal ulcers and has become the recommended treatment in all patients with this disease (9, 11, 12). In view of the frequency of duodenal ulcers in the general population and the health costs involved in treating them, numerous therapies have been investigated using several combinations of medications. Such work, however, often yielded contradictory results, which became a matter of controversy and debate (1, 13, 14). A regimen consisting of 1-wk triple therapy using a proton-pump inhibitor and two antibiotics has consistently shown high eradication rates and good tolerability (13, 15 20). In contrast, recent clinical studies have indicated that a 2-wk dual therapy with a proton-pump inhibitor and one antibiotic was less effective than a 1-wk triple therapy (13, 17, 21 23). A direct comparison of a modified 1-wk triple therapy consisting of the proton-pump inhibitor pantoprazole, clarithromycin, and metronidazole (PCM therapy) and a 2-wk dual therapy consisting of pantoprazole and clarithromycin (PC therapy) has, however, not been reported so far in a large patient population. Thus, the aim of the present study was to
2 1920 ADAMEK et al. AJG Vol. 93, No. 10, 1998 assess the efficacy of a 1-wk PCM therapy in comparison to a 2-wk PC therapy, using parallel groups of patients in a prospective, randomized, multicenter study. PATIENTS AND METHODS The study was designed as a prospective and randomized trial, involving centers (n 27) in Austria, Germany, and Switzerland. The investigation was conducted according to the Declaration of Helsinki and the guidelines for Good Clinical Practice. The study protocol was approved by the respective ethics committees. All patients gave their written informed consent to participate in the study. Inclusion and exclusion criteria Mobile male and female patients (median age, 48 yr; range, yr) were enrolled in the study. All patients had endoscopically proven duodenal ulcer (diameter 5mm and 20 mm) and H. pylori infection. At each study center all endoscopies were performed by the same endoscopist. During the initial examination a single biopsy was taken from the corpus and one from the antrum for use in the rapid urease test, indicating infection with H. pylori (Jatrox H. p. test, Röhm Pharma GmbH, Weiterstadt, Germany). In addition, the presence of H. pylori was confirmed with the 13 C-urea breath test (INFAI HPT, INFAI GmbH, Bochum, Germany). The breath samples were analyzed as described elsewhere (24). The breath sample was classified as positive if the excess Delta was 4% 13 CO 2. Exclusion criteria to enter the study were the presence of additional gastric ulcers, gastrointestinal malignancy, previous gastric surgery, pregnancy, lactation, concurrent severe diseases, concomitant treatment with potentially ulcerogenic medications such as nonsteroidal antiinflammatory drugs, suspected poor compliance, a known allergy to one of the study drugs, or treatment with proton-pump inhibitors, antibiotics, or bismuth salts during the last 4 wk before start of the study. Gastrointestinal symptoms Gastrointestinal symptoms experienced by the patients were assessed on entry into the study and at follow-up visits (days 7, 14, and 28 of the treatment). The symptoms included ulcer pain during the day and night, vomiting, nausea, retching, acid regurgitation, and heartburn; presence of these symptoms was conveyed by the patients and graded as mild, moderate, or severe. Hematological and biochemical parameters, as well as dipstick urine analysis, were performed at the individual study sites during the initial visit and then on days 7 and 14 of therapy for the PCM therapy and PC therapy groups, respectively. Study medications and protocol Study medications were oral tablets: 40 mg pantoprazole, 500 mg metronidazole, and 500 mg clarithromycin. To aid compliance the tablets were packed in blister packs and labeled morning, midday, and evening. Patients were randomized into two parallel treatment groups. Those in the PCM therapy group received, for 7 days, one pantoprazole, one clarithromycin, and one metronidazole tablet each morning and each evening before meals, and one metronidazole and one clarithromycin tablet each day before the midday meal. Subsequently, these patients took one pantoprazole tablet each morning until day 28 of the treatment schedule. Patients in the PC therapy group were treated, for 14 days, with one pantoprazole and one clarithromycin tablet each morning and each evening before meals and one clarithromycin tablet each day before lunch. Patients in the PC therapy group took one pantoprazole tablet each morning until day 28 of the treatment schedule. Patients were asked to report any adverse events to the physician. Eligibility for statistical evaluation included a compliance criterion whereby the consumption of the study medication had to be 75% for and 70% for the duodenal ulcer healing; this was checked by counting the study pills. Efficacy assessment was examined endoscopically on day 28; healing was defined as a complete reepithelialization of the ulcer crater with or without scarring; ulcer-related pain relief was judged by the severity of gastrointestinal symptoms on days 7, 14, and 28 of treatment. Eradication of H. pylori was checked by 13 C-urea breath test as described by Labenz et al. (24) on day 56 (4 wk after the cessation of treatment). Statistical analysis The number of patients required for the study was calculated to detect a difference of 20% in the eradication rates between the two study groups (Fisher s Exact Test). Based on a two-sided test, a significance level of 5%, and a power of 0.8, at least 100 patients per group were required to detect this difference. Results include the binomial 95% lower and upper confidence intervals (CI). Patient populations For both treatment regimens the statistical analysis of results was performed in three patient populations: intention-to-treat, per-protocol, and key point available. Definition of these terms and the investigated clinical parameters that these were applied to are shown in Table 1. The main analysis of rates and duodenal ulcer healing was performed per-protocol. Patients were excluded from this analysis if they had major protocol violations (such as not achieving the specified compliance with study medications or those whose follow-up visits fell outside the defined ranges). Patients who discontinued the study prematurely for reasons possibly related to the study medication were included in this analysis and classified as
3 AJG October 1998 PANTOPRAZOLE-BASED CURE FOR H. PYLORI 1921 TABLE 1 Definition of Patient Populations and the Evaluated Parameters Patient Population Definition Evaluated Parameter Intention-to-treat Ingestion of at least one dose of test medication Adverse events Per-protocol Completion of the entire treatment regimen, including medications, tests, and follow-up visits Symptoms Key point available Availability of test results for the 13 C-UBT at pretreatment and at the follow-up visit on day 56 Definitions of patient populations used for the statistical analysis of results obtained for the respective test parameters. 13 C-UBT, 13 C-urea breath test. TABLE 2 Demographic and Anthropometric Data Parameter/Protocol PCM Therapy PC Therapy Number of patients Median age (yr) Range Median height (cm) Range Median weight (kg) Range Median body mass index (kg/m 2 ) Range No previous history of duodenal 41 (29%) 48 (33%) ulcer (%) Duodenal ulcer relapse One (%) 15 (11%) 15 (11%) More than one (%) 86 (60%) 81 (56%) No previous diagnosis of H. pylori 115 (81%) 117 (81%) infection (%) Smokers (%) 76 (54%) 74 (51%) PCM therapy, triple therapy consisting of 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; PC therapy, dual therapy consisting of 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days. treatment failures. and duodenal ulcer healing rates were compared between the treatment groups by the Cochran-Mantel/Haenszel test using the method of odds ratios; the study centers were included in the analysis as a covariable. The possible influence by other factors, including the age, gender, smoking habits, body mass index, frequency of ulcer recurrence and duration of H. pylori infection upon eradication, and healing rates, were also investigated. Rates of complete ulcer pain relief were compared on days 7, 14, and 28 of the treatment using Fisher s Exact Test. RESULTS A total of 286 patients were enrolled into the study; their demographic and anthropometric data as well as patients histories are summarized in Table 2. At entry, almost all patients complained of epigastric pain or discomfort. There were no significant differences among the patients with respect to demographic and clinical parameters at the time of enrollment. TABLE 3 Patients Included in the Per-Protocol Statistical Evaluation* Parameter/Protocol PCM Therapy PC Therapy Number of patients Male/female 80/42 77/43 Number of patients Male/female 84/42 78/45 PCM therapy, triple therapy consisting of 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; PC therapy, dual therapy consisting of 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days. * The number of patients entered for evaluation of and duodenal ulcer healing differed slightly. This was due to either insufficient compliance or missed follow-up visits, making some patients ineligible for the evaluation of both parameters. The patients were randomized such that 142 received the PCM therapy and 144 the PC therapy. These patients represented the intention-to-treat population. Due to insufficient compliance or missed follow-up visits, some patients were not eligible for the evaluation of as well as duodenal ulcer healing. For this reason the actual patient numbers for the two investigated clinical parameters were not identical (Table 3). For the per-protocol analysis of and duodenal ulcer healing, respectively, 44 and 37 patients were excluded. Thus, a total of 242 patients were in the per-protocol analyses for the eradication of H. pylori; 122 were in the PCM and 120 in the PC therapy groups (Table 3). For the analysis of duodenal ulcer healing a total of 249 patients were included in the per-protocol analysis; of these 126 were in the PCM and 123 in the PC therapy groups (Table 3). In the per-protocol analysis, 116 of 122 patients (95% confidence interval [CI]: 90 98%) in the PCM therapy group demonstrated eradication of H. pylori, compared with 72/120 (60% CI: 51 69%) in the PC therapy group (p 0.001) (Fig. 1). Comparable differences between the two treatment schedules for rates were also observed for the other evaluated patient populations, namely, the key point available (116/119 [97% CI: 93 99%]
4 1922 ADAMEK et al. AJG Vol. 93, No. 10, 1998 FIG. 1. Comparison of rates after PCM and PC therapy. Statistical evaluation was performed from results in the following patient populations: intention-to-treat, per-protocol, and key point available. The number of patients (N) in each patient population, eradication rate (%), and p values are indicated. The Cochran-Mantel/Haenszel test was used to calculate the p values. in the PCM therapy and 72/113 [64% CI: 54 73%) in the PC therapy groups; p 0.001), as well as in the intentionto-treat (116/142 [82% CI: 74 88%] in the PCM therapy and 72/144 [50% CI: 42 58%] in the PC therapy groups; p 0.001) (Fig. 1). Other evaluated factors, including the age, gender, smoking, body mass index, frequency of ulcer recurrence or duration of H. pylori infection before entry into the study, had no effect upon the eradication rates in the PCM therapy group. In the PC therapy group, the eradication rates were higher for male than for the female patients (64% vs 53%) and in patients with relapsing ulcer disease, as compared with those with no previous ulcer history (65% vs 47%). The difference in the latter may possibly be due to higher compliance in patients suffering from duodenal ulcer disease for a longer time. For duodenal ulcer healing the rates were not significantly different between the two groups. After 28 days of treatment, complete ulcer healing occurred in 123/126 (98% CI: %) patients in the PCM therapy group and in 117/123 (95% CI: 90 98%) in the PC therapy group, p The results were similar when per-protocol and intention to treat patient populations were evaluated. Other factors such as age, gender, smoking habits, body mass index, previous history of ulcers, and H. pylori infection showed no effect upon the duodenal ulcer healing rates. Symptoms Relief from duodenal ulcer pain was also similar between the two study groups after 1, 2, and 4 wk of treatment. The differences between the two treatment regimens were not statistically significant. Of the patients who reported ulcer pain at entry, 101/122 (83% CI: 75 89%) in the PCM therapy and 100/120 (83% CI: 75 90%) in the PC therapy group were free from pain after 1 wk; after 2 wk the values were 111/121 (92% CI: 85 96%) and 106/118 (90% CI: 83 95%) in the PCM therapy and PC therapy groups, respectively; and by the fourth wk of treatment these values were 116/121 (96% CI: 91 99%) and 114/117 (97% CI: 93 99%), respectively. Adverse events, discontinuations, and laboratory analysis The most frequent adverse events observed during the course of this study included taste disturbance, diarrhea, and increased serum concentration of liver enzymes (Table 4). Patients in the PCM and PC therapy groups showed no other changes in their tested laboratory parameters after 1 and 2 wk of treatment, respectively. A total of 10 patients (3.4%) discontinued the study and were considered drop-outs. Of these, seven patients (three in the PCM and four in the PC therapy groups) discontinued due to adverse events that were likely related to the treatment, and three patients (all in the PC therapy group) discontinued due to lack of efficacy in the criterion of ulcer healing. These patients were evaluated as not healed and not eradicated in the per-protocol
5 AJG October 1998 PANTOPRAZOLE-BASED CURE FOR H. PYLORI 1923 TABLE 4 Incidence of Adverse Events in PCM and PC Therapy Groups* Parameter/Protocol PCM Therapy PC Therapy Number of patients Taste disturbance 12 (9%) 13 (9%) Diarrhea 11 (8%) 4 (3%) SGOT increased 9 (6%) 7 (5%) SGPT increased 9 (6%) 7 (5%) Nausea 4 (3%) 1% Abdominal pain 4 (3%) 1% * Adverse events reported at an incidence of 3% in patients who were treated according to PCM and PC therapy regimens. The calculations are based on the intention-to-treat patient population. PCM therapy, triple therapy consisting of 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; PC therapy, dual therapy consisting of 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days. SGOT, serum glutamic-oxaloactetic transaminase; SGPT, serum glutamate pyruvate transaminase. analysis of data. Other patients were excluded from the per-protocol analysis due to protocol violations (insufficient compliance or missed assessment visits). In the statistical evaluation of data, these patients were part of the intentionto-treat population. DISCUSSION Acceptance of a treatment schedule for the eradication of H. pylori depends on efficacy, tolerability, adverse events, complexity, and patient compliance. Several published clinical studies investigating schedules for effective eradication of H. pylori infections from the gastric mucosa have in the past provoked debate, often resulting in contentious recommendations (1, 11, 25 30). In a classic triple therapy consisting of bismuth and two antibiotics administered for 2 wk, the cure rates of H. pylori infection were high but the compliance was low (26, 27). In other protocols involving a proton-pump inhibitor together with amoxycillin or clarithromycin, the cure rates varied between 23 91%, depending on the study population and geographic region (1, 10, 31 33). On the other hand, recent studies have indicated that a 1-wk course of PCM therapy may be a reasonable and simple approach able to achieve reliable and consistent cure of H. pylori infection (15, 16, 18 20, 34). This proved correct in investigations with 1-wk PCM therapy in which more than 90% of patients were cured; the medications used included a proton pump inhibitor, together with the antibiotics clarithromycin and tinidazole (13) or clarithromycin and metronidazole (17). Because direct comparison of the PCM and PC therapies have not been reported heretofore, a prospective, multicenter study in two parallel groups of randomized patients was conducted. The present results show that the eradication rate of H. pylori was 95% after a 1-wk course of PCM therapy with pantoprazole, clarithromycin, and metronidazole. We found that this was significantly superior to a 2-wk PC therapy consisting of pantoprazole and clarithromycin, which achieved eradication of H. pylori in about 60% of patients (Fig. 1). The cure rates of H. pylori by the PCM therapy compare well with the highest eradication rates observed in other studies using triple regimens (25, 26). With respect to pretreatment resistance of H. pylori to antibiotics, it could be argued that resistance to metronidazole in particular may affect the efficacy of the 1-wk PCM therapy. Indeed, previous investigations showed that H. pylori resistance to metronidazole occurs in about 20 25% of patients; the cure rates, however, were not affected when clarithromycin was incorporated into the PCM therapy (21, 35). The high eradication rates of H. pylori observed by the PCM therapy in the present study suggests that resistance to metronidazole does not necessarily influence the success of the treatment (36). This study showed that 4 wk after the start of treatment, patients in both PCM and PC therapy regimens had similarly high rates of ulcer healing (PCM therapy, 98%; PC therapy, 95%). Such healing rates compare well with those observed in studies using 40 mg pantoprazole alone (18, 37 39). The treatment schedules were well tolerated and both the type and frequency of adverse events were equivalent. In conclusion, it could be shown that a 1-wk course of PCM therapy (comprising pantoprazole, clarithromycin, and metronidazole) is a simple, well-tolerated, highly potent regimen for the eradication of H. pylori infection. Hence, the PCM therapy represents a significantly superior schedule in comparison to the PC therapy (consisting of pantoprazole and clarithromycin). Our results support the concept that the 1-wk PCM therapy could become the standard therapeutic strategy for effective eradication of H. pylori infections in patients with duodenal ulcers. ACKNOWLEDGMENTS We thank the following persons: R. Dietrich, H. Dold, H. Khalil, P. Mateyka, G. Mönch, C. Riesenhuber, K. Rose, and G. Schilling for organizational activities involved with this multicenter and multinational study; R. Lühmann and A. Wiedemann for statistical evaluation; and C. Cain, R. Fischer, A. Schneider, K. B. Thomas, and W. Wurst for discussions, critical reading, and editing of the manuscript. This study was supported by a grant from Byk Gulden, Konstanz, Germany. Reprint requests and correspondence: PD Dr. R. J. Adamek, Medizinische Universitätsklinik St. Josef-Hospital, Gudrunstrasse 56, D-4479 Bochum, Germany. REFERENCES 1. Penston JG, McColl KE. Eradication of Helicobacter pylori: An objective assessment of current therapies. Br J Clin Pharmacol 1997;43: Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2: Rauws EA, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:
6 1924 ADAMEK et al. AJG Vol. 93, No. 10, Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116: Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: Seven-year follow-up. Lancet 1994; 343: Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328: Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut 1993;34: Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993;28: Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994;55: Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994;8: (review article). 11. Wilhelmsen I, Berstad A. Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994;29: Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol 1996;91: Goddard A, Logan RP. One-week low-dose triple therapy: New standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995;7: Harris AW, Misiewicz JJ. Treating Helicobacter pylori The best is yet to come? Gut 1996;39: Jaup BH, Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995;90: Moayyedi P, Sahay P, Tompkins DS, et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995;7: Labenz J, Stolte M, Ruhl GH, et al. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995;7: Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: Bardhan KD. Triple therapy as a cure for Helicobacter pylori infection. Eur J Clin Pharmacol 1996;8:S Frevel M, Daake H, Janisch HD, et al. Pantoprazole plus claritromycin and metronidazole versus pantoprazole plus claritromycin and amoxycillin for therapy of H. Pylori infection. Gastroenterology 1997;112:(4, supplement)a119b. 21. Adamek RJ, Szymanski C, Pfaffenbach B, et al. Kurzzeit-Tripel- Therapie mit Pantoprazol, Clarithromycin und Metronidazol zur Heilung der Helicobacter-pylori-Infektion. (Short-term triple treatment of Helicobacter pylori infection with pantoprazole, clarithromycin and metronidazole.) Dtsch Med Wochenschr 1995;120: Adamek RJ, Opferkuch W, Wegener M. Modified short-term triple therapy ranitidine, clarithromycin, and metronidazole for cure of Helicobacter pylori infection. Am J Gastroenterol 1995;90:168 9 (letter). 23. Delchier JC, Elamine I, Goldfain D, et al. Comparison of omeprazole amoxicillin versus omeprazole amoxicillin clarithromycin in the eradication of Helicobacter pylori (Hp) results from a randomized study involving 120 patients. Gastroenterology 1995;108:(4 suppl)a81 (abstract). 24. Labenz J, Stolte M, Aygen S, et al. Qualitative und semiquantitative invasive und nicht-invasive Diagnostik der Helicobacter pylori-kolonisation der gastralen Mukosa. (Qualitative and semiquantitative invasive and noninvasive diagnosis of Helicobacter pylori colonization of gastric mucosa.) Z Gastroenterol 1993;31: Pajares-Garcia J, Bazzoli F. Eradication. In: Malfertheiner P, Megraud F, Michetti P, Price A, eds. The year in Helicobacter pylori Curr Opin Gastroenterol 1996;12 (suppl 1): Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87: Labenz J, Gyenes E, Ruhl GH, et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: A prospective, randomized, and controlled study. Gut 1993;34: de Boer WA, Driessen WM, Potters VP, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994;89: de Boer WA. Re: [ 13 C]urea breath test. Am J Gastroenterol 1995;90: Penston JG, Mistry KR. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther 1996;10: Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994;29 (suppl 201): Penston JG. Helicobacter pylori eradication understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8: (review article). 33. Delchier JC, Elamine I, Goldfain D, et al. Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996;10: Bazzoli F, Zagari R, Fossi S, et al. Efficacy and tolerability of a short term, low dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 1993;104(No. 4 suppl):a40 (abstract). 35. Adamek RJ, Opferkuch W, Pfaffenbach B, et al. Cure of Helicobacter pylori infection: Role of duration of treatment with omeprazole and amoxicillin. Am J Gastroenterol 1996;91: Tytgat GN. Antimicrobial therapy for Helicobacter pylori infection. Helicobacter 1997;2 (suppl 1):S Schepp W, Classen M. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. Scand J Gastroenterol 1995;30: Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994;8 (suppl 1): Beker JA, Bianchi Porro G, Bigard MA, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationThe role of antisecretory drugs in the treatment of Helicobacter pylori infection
Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21 25. The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationHelicobacter pylori eradication in chronic duodenal ulcer disease - a community-based study
Postgrad MedJ 1995; 71: 413-418 The Fellowship of Postgraduate Medicine, 1995 Original articles Northwick Park Hospital, Harrow, Middlesex HA1 3UJ, UK Department of Gastroenterology PS Phull SD Ryder AJ
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationTitle. Author(s)Kato, Mototsugu. Issue Date Doc URL. Type. Note. File Information.
Title Effects of lansoprazole plus amoxycillin on the cure Author(s)Kato, Mototsugu Issue Date 1996-12-25 Doc URL http://hdl.handle.net/2115/32629 Type theses (doctoral) Note 共著者あり 共著者名 :Asaka Masahiro,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/59359
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationThe long-term management of patients with bleeding duodenal ulcers
Aliment Pharmacol Ther (1997); 11: 505±510. The long-term management of patients with bleeding duodenal ulcers M. E. MCALINDON, J. S. W. TAYLOR & S. D. RYDER Department of Medicine, University Hospital,
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationTreatment of Helicobacter pylori in Patients With Duodenal Ulcer Hemorrhage A Long-Term Randomized, Controlled Study
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 95, No. 9, 2000 2000 by Am. Coll. of Gastroenterology ISSN 0002-9270/00/$20.00 Published by Elsevier Science Inc. PII S0002-9270(00)01041-8 Treatment of Helicobacter
More informationUrea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013
MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationORIGINAL INVESTIGATION. Maintenance Treatment Is Not Necessary After Helicobacter pylori Eradication and Healing of Bleeding Peptic Ulcer
ORIGINAL INVESTIGATION Maintenance Treatment Is Not Necessary After Helicobacter pylori Eradication and Healing of Bleeding Peptic Ulcer A 5-Year Prospective, Randomized, Controlled Study Chen-Chiung Liu,
More informationThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study
Aliment Pharmacol Ther 2001; 15: 843±849. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study B. C. Y. WONG*, W. H. WANG*, W.M.WONG*,G.K.K.LAU*,F.M.Y.FUNG*,N.N.S.KUNGà,
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationOmeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni
Gut 1995; 37: 477-481 Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni 477 Centre for Digestive Diseases, Five Dock, NSW, Australia T J Borody P Andrews G Fracchia S Brandl
More informationI. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD
A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationTreatment of H. pylori Infection: The Reality
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee
More informationHelicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment
Aliment Pharmacol Ther 2003; 18: 93 100. doi: 10.1046/j.0269-2813.2003.01649.x Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten,
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationBismuth subsalicylate in the treatment of H2 blocker
Gut, 1992, 33, 179-183 Departments of Gastroenterology and Hepatology and Clinical Microbiology, Medizinische Hochschule Hannover, Germany S Wagner M Gebel W Bar P Lange J Freise F W Schmidt Department
More informationYang K. Chen, MD* Prahalad Jajodia, MD Lino DeGuzman, MD Shahid A. Khan, MD Vaman S. Jakribettuu, MD*
Randomized Controlled Trial Comparing Proton Pump Inhibitor- Based Eradication Regimen versus Low-Cost Eradication Regimen for Patients with Helicobacter pylori with Uninvestigated Dyspepsia Yang K. Chen,
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationThe effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori
Aliment Pharmacol Ther 1999; 13: 667±673. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori A. PILOTTO*, G. LEANDRO, M. FRANCESCHI*, M. RASSUà,
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationEradication of Helicobacter pylori: an objective assessment of current therapies
Br J Clin Pharmacol 1997; 43: 223 243 Eradication of Helicobacter pylori: an objective assessment of current therapies J. G. Penston & K. E. L McColl 1 Scunthorpe General Hospital, Scunthorpe and 1 Department
More informationEffect of Helicobacter pylori infection and its eradication on nutrition
Aliment Pharmacol Ther 2002; 16: 799 806. Effect of Helicobacter pylori infection and its eradication on nutrition T. FURUTA*, N. SHIRAI*, F. XIAO*, M. TAKASHIMA* & H. HANAI *First Department of Medicine
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology0815-93192005 Blackwell Publishing Asia Pty Ltd206935940Original ArticleLow-dose rabeprazole-based triple therapywm Wong et
More information(Index words: Clarithromycin, compliance, efficacy, tinidazole and omeprazole therapy)
Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study HA de Silva 1, J Hewavisenthi 2, A Pathmeswaran
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationGeneral practice. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model A E Duggan, K Tolley, C J Hawkey, R F A Logan Department of Public Health and Epidemiology,
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationHelicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:1032 1036 PERSPECTIVE Helicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results DAVID Y. GRAHAM Department of Medicine,
More informationDrug Class Review Proton Pump Inhibitors
Drug Class Review Proton Pump Inhibitors Evidence Tables April 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on this
More informationTHE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 98, No. 12, by Am. Coll. of Gastroenterology ISSN /03/$30.00
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 98, No. 12, 2003 2003 by Am. Coll. of Gastroenterology ISSN 0002-9270/03/$30.00 Published by Elsevier Inc. doi:10.1016/j.amjgastroenterol.2003.07.003 An Update
More informationHealth technology The use of four different combined treatments for Helicobacter pylori (H. pylori) infection. These were:
Tratamiento de la infeccion por Helicobacter pylori en pacientes con ulcera duodenal: estudio de costo-beneficio [Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit
More informationHelicobacter pyloni and upper gastrointestinal
314 Helicobacter pyloni and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom Gut 1995; 37: 314-318 R Milne, R P H Logan, D Harwood, J J Misiewicz, D Forman Health Services
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationHelicobacter Connections. Barry Marshall
Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting
ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationEfficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection
Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection Ramin Talaie Modarress Hospital, Shahid Beheshti University of Medical Sciences,
More informationRole of Helicobacter pylori in ulcer healing and
22 Departments of Gastroenterology G Bianchi Porro F Parente V Imbesi and Rheumatology F Montrone I Caruso L Sacco University Hospital, Milan, Italy Correspondence to: Professor G Bianchi Porro, Gastrointestinal
More informationArab Journal of Gastroenterology
Arab Journal of Gastroenterology 14 (2013) 1 5 Contents lists available at SciVerse ScienceDirect Arab Journal of Gastroenterology journal homepage: www.elsevier.com/locate/ajg Original Article Penbactam
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationOriginal article J Bas Res Med Sci 2015; 2(4):45-50.
Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationThe treatment of helicobacter pylori infection and its sequelae with emphasis on nitroimidazole resistance Wouden, Egbert-Jan van der
University of Groningen The treatment of helicobacter pylori infection and its sequelae with emphasis on nitroimidazole resistance Wouden, Egbert-Jan van der IMPORTANT NOTE: You are advised to consult
More informationThe Nobel Prize in Physiology or Medicine for 2005
The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer
More information헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구
Korean J Gastroenterol Vol. 70 No. 4, 176-180 https://doi.org/10.4166/kjg.2017.70.4.176 pissn 1598-9992 eissn 2233-6869 ORIGINAL ARTICLE 헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구 박혜윤, 강은정, 김동근, 김기주,
More informationRole of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication
Aliment Pharmacol Ther 2000; 14: 1639±1643. Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication S. TORACCHIO*, L. CELLINI, E.DICAMPLI, G.CAPPELLO*,M.G.MALATESTA*,A.FERRI*,
More informationComparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT
Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in
More informationORIGINAL INVESTIGATION. infection has resulted in ulcer healing and a significant
ORIGINAL INVESTIGATION A Comparison of 10 and 14 Days of Lansoprazole Triple Therapy for Eradication of Helicobacter pylori M. Brian Fennerty, MD; T. O. G. Kovacs, MD; R. Krause, MD; M. Haber, MD; A. Weissfeld,
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationIntragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic
Gut 1995; 37: 39-43 Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin 39 J Labenz, M Stolte, A L Blum,
More informationThe diagnosis and management of H. pylori infection in Singapore
Singapore Med J 2017; 58(5): 234-240 doi: 10.11622/smedj.2017037 CMEArticle The diagnosis and management of H. pylori infection in Singapore Claire Alexandra Zhen Chew 1, MBChB, Tong Fong Lye 2, MBBS,
More informationEfficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection
ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei
More informationEfficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2012.15.4.237 Pediatric Gastroenterology, Hepatology & Nutrition 2012 December 15(4):237-242 Original Article PGHN Efficacy of Proton Pump
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationProton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION
Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter
More informationClinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
BioMed Research International Volume 2015, Article ID 163960, 6 pages http://dx.doi.org/10.1155/2015/163960 Clinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter
More informationIntragastric Acidification Reduces the Occurrence of False-Negative Urea Breath Test Results in Patients Taking a Proton Pump Inhibitor
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 4, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)02250-X Intragastric Acidification
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationHelicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer
ORIGINAL ARTICLE ISSN 1738-3331, https://doi.org/10.7704/kjhugr.2018.18.1.30 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018;18(1):30-37 Helicobacter pylori Eradication in
More informationKEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.
INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY Karunamoorthy Rajachidambaram 1, Dinkaran Kaarthesan
More informationHelicobacter pylori resistance in the Netherlands: a growing problem?
ORIGINAL ARTICLE Helicobacter pylori resistance in the Netherlands: a growing problem? R. Ruiter 1,2 *, H.F. Wunderink 3, R.A. Veenendaal 5, L.G. Visser 4, M.G.J. de Boer 4 Departments of 1 Internal Medicine,
More informationRapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.
Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong
More informationAn evaluation of whole blood testing for Helicobacter pylori in general practice
Aliment Pharmacol Ther 1998; 12: 641±645. An evaluation of whole blood testing for Helicobacter pylori in general practice N. J. TALLEY, J. R. LAMBERT*, S. HOWELL, H. H.-X. XIA, S. K. LIN* & L. AGREUS
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More informationSuccess Rate of Furazolidone Based Triple Therapy for Eradication of Helicobacter Pylori in Children
Original Article Iran J Pediatr Sep 2008; Vol 19 (No 3), Pp:244-248 Success Rate of Furazolidone Based Triple Therapy for Eradication of Helicobacter Pylori in Children Mehri Najafi, MD* 1 ; Ahmad Khodadad,
More information